NSRX: חוב כולל להון Nasus Pharma Ltd

The development of innovative nasal sprays for antiviral combat and emergency therapy relies on unique mucosal delivery methods, where high drug absorption rates serve as the key success factor. The market trend on the GURU.Markets platform for the debt-to-equity ratio is 0.01. Nasus Pharma Ltd (NSRX) maintains its status as a reliable creator of defensive powder-based agents, benefiting from steady recognition within the medical community.

To find a balance between the cost and quality of an asset, it is essential to evaluate financial leverage through the debt-to-equity ratio, which determines the business's degree of dependence on creditors. In the case of Nasus Pharma Ltd (NSRX), this calculation reflects the ability to fund innovative intranasal developments without excessive debt pressure, as clearly demonstrated by the price action of the total debt-to-equity ratio.